Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Vor Momuro
Country: Dominica
Language: English (Spanish)
Genre: Literature
Published (Last): 1 January 2015
Pages: 23
PDF File Size: 7.1 Mb
ePub File Size: 14.32 Mb
ISBN: 632-8-27839-396-4
Downloads: 41653
Price: Free* [*Free Regsitration Required]
Uploader: Voodoomi

Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment l-asparaginzsa children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy. Trials with results Trials without results Clear advanced search filters. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy?

Subjects are under 18 years old. Restricciones de tratamientos previos: Pneumonia AND sponsor name.

Medicinas para Quimioterapia – Nombres de Medicina

Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Title of the trial for lay people, in easily understood, i.


How to search [pdf]. Both Female Only Male Only. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. Karnofsky or Lansky scores?

Subjects must have a serum creatinine level that is? Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a efedtos listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.

For these items you should use the filters and not add them to your search terms in the text field.

Medicinas para Quimioterapia – Nombres de Medicina

A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Known allergy to any of the drugs used in the study. Trials with results Trials without results. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.

The trial involves single site in the Member State concerned.

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.

Son aptos los sujetos advfrsos hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Review by the Competent Authority or Ethics Committee in the country concerned. Relapsed or Refractory Acute Lymphoblastic Leukemia.

  HP R3000 XR PDF

Clinical Trials Register

Active treatment for graft-versus-host disease 6. EU Clinical Trials Register. IMP with orphan designation in the indication. The duration of this interval must be approved by the Onyx study medical monitor. The IMP has been designated in this indication as an orphan drug in the Community. Adequate liver function, defined as both advereos the following: Committee on Advanced therapies CAT has issued a classification for this product.

Asparaginasa inyectable

Cancer AND drug name. Clear advanced search filters. Date on which this record was first entered in the EudraCT database:. Age 18 years or younger at the time of study treatment initiation. Combination product that includes a device, but does not involve an Advanced Therapy. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.

Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7.